1911564-39-0
1911564-39-0
Chemical Structure
PI3Kδ-IN-1
- CAS No.: 1911564-39-0
- Formula:C22H20F3N7O2
- Molecular Weight:471.44
IUPAC Name: 2-(4-acetyl-3,3-dimethyl-2-oxopiperazin-1-yl)-4-(4-amino-5-(trifluoromethyl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)benzonitrile
InChIKey: ZDXIDBRGTYDHBQ-UHFFFAOYSA-N
SMILES: NC1=NC=NN2C1=C(C(F)(F)F)C=C2C3=CC=C(C#N)C(N4CCN(C(C)=O)C(C)(C)C4=O)=C3
Biological Activity: PI3Kδ-IN-1 is a potent, selective, and efficacious PI3Kδ inhibitor with an IC50 of 1.7 nM.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PI3Kδ-IN-1 | 99.68% | PI3Kδ-IN-1 is a potent, selective, and efficacious PI3Kδ inhibitor with an IC50 of 1.7 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PI3Kδ-IN-1 (Standard) | ≥98% | PI3Kδ-IN-1 (Standard) is the analytical standard of PI3Kδ-IN-1 (HY-101921). This product is intended for research and analytical applications. PI3Kδ-IN-1 is a potent, selective, and efficacious PI3Kδ inhibitor with an IC50 of 1.7 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Darovasertib | 99.78% | Darovasertib (LXS196) is a potent, selective and orally active protein kinase C (PKC) inhibitor, with IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. Darovasertib has the potential for uveal melanoma research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PF-05180999 | 99.96% | PF-05180999 (PF-999) is a phosphodiesterase 2A (PDE2A) inhibitor, with an IC50 of 1.6 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
I-191 | 99.14% | I-191 is a potent, selective protease-activated receptor 2 (PAR2) antagonist. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ABM-14 | 98.10% | ABM-14 is a ligand for targeting androgen receptor (AR) for PROTAC. ABM-14 binds to a ligand for VHL via linker to form ARCC-4 (HY-130492) to degrade AR. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
EOC317 | 98.01% | EOC317 (ACTB-1003) is an oral kinase inhibitor with IC50s of 6, 2 and 4 nM for FGFR1, VEGFR2 and Tie-2. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PROTAC AR/AR-V7 degrader-1 | 99.72% | PROTAC AR/AR-V7 degrader-1 (27c) is a PROTAC-based and dual AR, AR-V7 degrader, with DC50 values of 2.67 and 2.64 μM for AR and AR-V7, respectively. PROTAC AR/AR-V7 degrader-1 (27c) induces apoptosis (Red: AR antagonist; Blue: E3 ligase ligand; Black: linker). |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ID11916 | ID11916 is an orally active androgen receptor (AR) antagonist and a phosphodiesterase 5 (PDE5) inhibitor. ID11916 blocks androgen binding to AR, nuclear translocation, and androgen-dependent transcriptional activity of AR, while increasing intracellular cGMP levels and activating PKG via inhibition. ID11916 shows potent anti-cancer effect in prostate cancer cell lines VCaP and 22Rv1 and in AR-positive breast cancer cell lines SK-BR-3. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RET ligand-5 | RET ligand-5 is a PROTAC target protein ligand that can be used for synthesis of PROTACs, such as PROTAC RET Degrader 1 (HY-178964). PROTAC RET Degrader 1 is a potent RET PROTAC degrader with anti-tumor activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GSK2606414 | 99.91% | GSK2606414 is a cell-permeable and orally available protein kinase R-like endoplasmic reticulum (ER) kinase (PERK) inhibitor with an IC50 of 0.4 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Enzalutamide carboxylic acid | 98.60% | Enzalutamide carboxylic acid (MDV3100 carboxylic acid) is an inactive metabolite of Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
